Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Have you evaluated the performance of Exelixis' (EXEL) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this drug developer, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has be ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several quarters. To see what I am targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Mid-cap oncology concern Exelixis, Inc. (NASDAQ: EXEL ) posted more than solid first-quarter results after the bell on Tuesday. Management also raised forward guidance significantly. The company is going through somewh ...

Exelixis (EXEL) Conference Call Summary Company Overview - **Company**: Exelixis, Inc. (EXEL) - **Event**: BofA Annual Healthcare Conference - **Date**: May 14, 2025 Key Points Industry and Company Performance - Exelixis is focused on improving cancer care, particularly through its lead product, cabozantinib (cabo) [3][4] - The company reported strong Q1 performance with a 35% year-over-year growth in total revenue [19] - The commercial organization is described as "best in class" within the biopharma oncology ecosystem [4] Financial Highlights - Exelixis has a strong balance sheet and free cash flow, with approximately $700 million in free cash flow last year, primarily used for share buybacks [10][11] - The company has executed a buyback program, repurchasing about 19%-20% of its float since early 2023, with an additional $500 million approved for buybacks [6][7] - R&D spending is committed to remain around $1 billion annually to support pipeline development [7][9] Pipeline and Product Development - The company is optimistic about the potential of its pipeline, particularly with cabozantinib and Zanza, and is actively seeking additional compounds to enhance its portfolio [8][56] - The recent approval of cabozantinib for NET (neuroendocrine tumors) is expected to drive further growth, with a focus on capturing market share [20][21] - The company is also exploring opportunities in colorectal cancer (CRC) with Zanza, aiming for a broader indication [40][41] Market Strategy and Competitive Position - Exelixis emphasizes a scientific and analytical approach to market share growth, actively engaging with prescribers to educate them about their products [22][23] - The company is positioned uniquely in the market, being the only branded drug in the oral therapy market for NET, which is seen as a significant advantage [26] - The potential for Zanza to capture a larger market share in CRC is highlighted, with expectations of a similar growth trajectory as seen in renal cancer [27] Future Outlook - The company is optimistic about the upcoming data readouts for Zanza and its potential impact on market positioning [49][50] - Exelixis is focused on building franchises and leveraging partnerships, particularly with Merck, to enhance its research capabilities and market presence [48][72] - The management is committed to maintaining operational discipline while exploring growth opportunities, ensuring that investments are aligned with potential returns [14][15] Additional Insights - The company acknowledges the challenges faced in the past but expresses confidence in overcoming these hurdles with a strong team and strategic focus [4][5] - There is a clear emphasis on the importance of data and evidence in driving market acceptance and physician adoption of their therapies [59][61] This summary encapsulates the key insights from the Exelixis conference call, highlighting the company's strategic direction, financial health, and market opportunities within the oncology sector.

Core Viewpoint - Exelixis, Inc. reported strong first-quarter 2025 results, exceeding earnings expectations and showing significant revenue growth driven by its lead drug, Cabometyx [1][2]. Financial Performance - Adjusted earnings were 62 cents per share, surpassing the Zacks Consensus Estimate of 42 cents, and up from 17 cents per share in the same quarter last year [1][2]. - Net revenues reached $555.4 million, exceeding the Zacks Consensus Estimate of $503 million, and reflecting a 31% year-over-year increase [2]. - Net product revenues were $513.3 million, a 36% increase year-over-year, primarily due to higher sales volume and average net selling price of Cabometyx [3]. Product Performance - Cabometyx generated revenues of $510.9 million, beating the Zacks Consensus Estimate of $433.7 million and the model estimate of $457.3 million [4]. - Collaboration revenues totaled $42.2 million, a decrease of 10% from $46.7 million in the previous year, attributed to lower royalty revenues from collaboration partners [5]. Expense Management - Research and development expenses amounted to $212.2 million, down 7% year-over-year, due to reduced collaboration costs and lower clinical study costs [6]. - Selling, general and administrative expenses increased by 20% year-over-year to $137.2 million, driven by higher personnel and marketing expenses [6]. Guidance and Future Outlook - Exelixis raised its 2025 sales guidance, now expecting total revenues between $2.25 billion and $2.35 billion, up from the previous range of $2.15 billion to $2.25 billion [8]. - The company anticipates research and development expenses in the range of $925 million to $975 million and selling, general and administrative expenses between $475 million and $525 million for 2025 [10]. Regulatory and Pipeline Updates - In March 2025, Exelixis received FDA approval for the label expansion of Cabometyx for treating neuroendocrine tumors, making it the first systemic treatment approved for this indication [11][12]. - The company is also developing zanzalintinib, with promising results from a phase Ib/II trial showing better efficacy when combined with Tecentriq [13][14].

Core Insights - Exelixis reported a revenue of $555.45 million for the quarter ended March 2025, marking a 30.6% increase year-over-year and exceeding the Zacks Consensus Estimate by 10.44% [1] - The company's EPS for the quarter was $0.62, significantly up from $0.17 in the same quarter last year, resulting in an EPS surprise of 47.62% compared to the consensus estimate of $0.42 [1] Revenue Breakdown - Net product revenues reached $513.28 million, surpassing the average estimate of $448.24 million by nine analysts, reflecting a year-over-year increase of 35.6% [4] - CABOMETYX generated $510.87 million in net product revenues, exceeding the estimated $433.73 million by seven analysts, with a year-over-year growth of 35.7% [4] - COMETRIQ's net product revenues were $2.41 million, compared to the estimated $3.39 million, showing a year-over-year increase of 14.5% [4] - License revenues totaled $42.48 million, falling short of the average estimate of $44.61 million, representing a year-over-year decline of 4.9% [4] - Collaboration services reported a loss of $0.32 million, significantly below the average estimate of $2.43 million, indicating a drastic year-over-year change of -115.6% [4] Stock Performance - Over the past month, Exelixis shares have returned +3.5%, while the Zacks S&P 500 composite has increased by +9.1%, suggesting underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it may perform in line with the market in the near term [3]

TUESDAY, MAY 13, 2025 First Quarter 2025 Financial Results Commercial Update Development Update Pipeline & Discovery Update Nasdaq: EXEL Today's Agenda Introduction First Quarter 2025 Highlights Financial Results & Guidance Q&A Susan Hubbard EVP, Public Affairs and Investor Relations Michael M. Morrissey, Ph.D. President and CEO Chris Senner EVP and CFO PJ Haley EVP, Commercial Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Resea ...

Exelixis (EXEL) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 47.62%. A quarter ago, it was expected that this drug developer would post earnings of $0.51 per share when it actually produced earnings of $0.55, delivering a surprise of 7.84%.Over the last four quarters, the company h ...

Exelixis (EXEL) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IRMichael Morrissey - CEO, President & DirectorChristopher Senner - Executive VP & CFOP.J. Haley - EVP, CommercialAmy Peterson - Executive VP, Product Development & Medical Affairs and Chief Medical OfficerDana Aftab - Executive VP of Discovery and Translational Research & Chief Scientific OfficerMichael Schmidt - Senior Managing Director, Equity ResearchSilvan Türkcan - Managing Direc ...